Arkolith/Insider Trading/VRCA/Form 4

Stalfort John A III

DirectorVerrica Pharmaceuticals Inc. (VRCA) · full profile →Form 4 · filed Nov 26, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 26, 2024Gift(G)50K—$01.9M
Nov 22, 2024Buy(P)1.1M——1.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 22, 2024Buy(P)562K——562K
Nov 22, 2024Buy(P)562K——562K

Transaction Codes

G
Gift
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-027710) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML